Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has upgraded Atea Pharmaceuticals (NASDAQ:AVIR) from Underweight to Equal-Weight and raised the price target from $2 to $6.88.
August 13, 2024 | 9:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley analyst Matthew Harrison has upgraded Atea Pharmaceuticals from Underweight to Equal-Weight and increased the price target from $2 to $6.88.
The upgrade from Underweight to Equal-Weight and the significant increase in the price target from $2 to $6.88 by a reputable analyst at Morgan Stanley is likely to positively impact the stock price of Atea Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100